Strive to serve and create value
Barrigen is currently focused on developing novel oncolytic virus therapies with our increasing deepened knowledge ...
FIND OUT MOREBarrigen has developed a robust pipeline, leveraging state-of-art science and technologies to creative novel oncolytic viruses for various cancer treatment.
BREV-1 induces selective tumor lysis while leaving healthy cells mostly. In addition to oncolytic effect...
LEARN MOREBREV-718 is a novel engineered virus in Barrigen’s oncolytic virus platform and is in ...
LEARN MORE